Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 126 participants.
Also called NCT05199090
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 126 participants
- Sponsor
- Registry
-
NCT05199090 -
2021-004449-19
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT05199090. Randomized; double masking; primary purpose treatment. Start 2022-02-10 (actual); primary completion 2023-05-11 (actual). Results posted on 2024-05-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
- Condition
- Obesity
- Intervention (Drug)
- MBL949
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05199090- Content hash
bd1134721102c16e1a68886896323c759541c7a71633ce794224c8b5a98174ae